Spots Global Cancer Trial Database for Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
Official Title: An Open Label, Randomized, Phase II Study of AS1404 in Combination With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
Study ID: NCT00111618
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.
Detailed Description: The overall aim of this study is to determine the safety, tolerability and efficacy of AS1404 in combination with docetaxel in patients with hormone refractory metastatic prostate cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Central Hematology Oncology Medical Group Inc, Alhambra, California, United States
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Providence Saint Joseph's Medical Center (PSJMC), Burbank, California, United States
Pacific Oncology & Hematology Associates, Encinitas, California, United States
Virginia K. Crosson Cancer Center, Fullerton, California, United States
Pacific Shores Medical Group, Long Beach, California, United States
UCLA Clinical Research Unit, Los Angeles, California, United States
North Valley Hematology/Oncology Medical Group, The Thomas and Dorothy Leavey Cancer Center, Northridge, California, United States
Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
Cancer Care Associates Medical Group, Inc, Redondo Beach, California, United States
Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States
Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States
Central Coast Medical Oncology Corporation, Santa Maria, California, United States
Stanford University Medical Center-Cancer Center, Stanford, California, United States
University of Miami School of Medicine, Miami, Florida, United States
Peachtree Hematology and Oncology, Atlanta, Georgia, United States
Oncology Hematology Associates of Central Illinois,PC, Peoria, Illinois, United States
Ochsner Cancer Institute, New Orleans, Louisiana, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Park Nicollet Institute, St Louis Park, Minnesota, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Biomedical Research Alliance of New York (BRANY), Bronx,, New York, United States
Columbia University Medical Center, New York, New York, United States
Staten Island Urological Research, Staten Island, New York, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
University of Virginia Health System, Charlottesville, Virginia, United States
Marshfield Clinic Foundation, Marshfield, Wisconsin, United States
Contact Details
Name: Roberto Pili, MD
Affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
